IFPA WPPAC 2021 Highlights Podcast

 

In this episode, Medicom’s correspondent covers 6 presentations held at the International Federation of Psoriasis Associations 6^th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) that took place 30 June to 3 July 2021.

The topics discussed are:

1. 
   
   1. Based on the findings of the phase 3 POETYK PSO-1 and PSO-2 trials, deucravacitinib, a once-daily oral selective TYK2 inhibitor, has the potential to become an efficacious and well-tolerated treatment of choice for patients with moderate-to-severe plaque psoriasis.
   2. The first randomised, placebo-controlled trial in patients with generalised pustular psoriasis showed that IL-36 receptor inhibition with spesolimab resulted in rapid improvements in signs and symptoms of flares versus placebo, with sustained effects and a favourable benefit-risk profile
   3. Although treatment with immune checkpoint inhibitors was associated with frequent disease exacerbations in patients with pre-existing psoriasis, flares were manageable with standard psoriasis treatment. Few patients required discontinuation of ICIs. In addition, this multicentre study from the USA revealed excellent tumour outcomes.
   4. The duodenum of psoriasis patients is characterised by subclinical inflammation. In half of patients, the gut mucosa had an increased permeability. This study, which was awarded the best scientific poster, fits very well into the discussion about the gut–skin axis and the importance of the microbiome in psoriasis and psoriatic arthritis.
   5. Patients with moderate-to-severe psoriasis treated with a biologic drug have a similar or possibly lower risk of contracting COVID-19 compared with the general population (0.3% vs 1.8%). That was found in a multicentre cohort study from Canada, awarded the ‘Best young researcher poster’. These findings can guide physicians in continuing biologic therapy during the pandemic.
   6. Cardiovascular comorbidities are a large problem for patients with psoriatic diseases. A cross-sectional, observational, and comparative study from Mexico, awarded the ‘Nature Reviews Rheumatology poster prize’, presented a practical solution to try and improve the calculation of the CV risk.

 

Copyright ©2021 Medicom Medical Publishers



Posted on 20 July 202127 June 2024